Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.79 |
| ▸ | ERBB2 | P04626 | 7/20 | 0.79 |
| ▸ | KDR | P35968 | 3/20 | 0.79 |
| ▸ | FBP1 | P09467 | 2/20 | 0.79 |
| ▸ | AURKA | O14965 | 1/20 | 0.79 |
| ▸ | INSR | P06213 | 1/20 | 0.79 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.79 |
| ▸ | FLT4 | P35916 | 1/20 | 0.79 |
| ▸ | CLK1 | P49759 | 1/20 | 0.79 |
| ▸ | EPHB4 | P54760 | 1/20 | 0.79 |
| ▸ | TEK | Q02763 | 1/20 | 0.79 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.79 |
| ▸ | HDAC3 | O15379 | 5/20 | 0.74 |
| ▸ | HDAC4 | P56524 | 5/20 | 0.74 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.74 |
| ▸ | HDAC7 | Q8WUI4 | 5/20 | 0.74 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.74 |
| ▸ | HDAC10 | Q969S8 | 5/20 | 0.74 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.74 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15217638 | 0.92 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL15217643 | 0.92 | EGFR (0.79) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL907212 | 0.91 | KDR (0.71) | EGFRERBB2KDREPHB4AURKB | |
| SCHEMBL20305795 | 0.91 | EGFR (0.74) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL642542 | 0.91 | HDAC3 (0.83) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL641952 | 0.89 | EGFR (0.73) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL2099106 | 0.89 | EGFR (1.00) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL30505605 | 0.89 | EGFR (1.00) | EGFRERBB2KDRFBP1AURKA | |
| Hydrochloric Acid SCHEMBL27887194 | 0.88 | EGFR (0.98) | EGFRERBB2KDRFBP1AURKA | |
| SCHEMBL22336753 | 0.87 | FBP1 (0.92) | EGFRERBB2KDRFBP1AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2634178-B1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | CHINESE ACAD INST CHEMISTRY (CN) | 2016-08-24 | — | — | EP | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-9233995-B2 | Quinazoline derivatives and quinazoline complex protein kinase inhibitor for inhibiting multiplication of tumor cells and preparation method thereof | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCES (CN) | 2016-01-12 | — | — | US | disclosed |
| US-20140243239-A1 | MULTIPLEXED KINASE INHIBITOR BEADS AND USES THEREOF | NIH-DEITR | 2014-08-28 | — | — | US | disclosed |
| EP-2634178-A1 | QUINAZOLINE DERIVATIVE AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICATION OF TUMOR CELLS AND PREPARATION METHOD THEREOF | Institute Of Chemistry, Chinese Academy Of Sciences (CN) | 2013-09-04 | — | — | EP | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | INSTITUTE OF CHEMISTRY, CHINESE ACADEMY OF SCIENCE (CN) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225811-A1 | QUINAZOLINE DERIVATIVES AND QUINAZOLINE COMPLEX PROTEIN KINASE INHIBITOR FOR INHIBITING MULTIPLICAITON OF TUMOR CELLS AND PREPARATION METHOD THEREOF | MAP3K21, MAP3K15, MAP3K14 | EGFR 225/4885ERBB2 115/4885KDR 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.